30 results about "CYP2E1" patented technology

The invention discloses a kit for testing the genetic risk of esophageal cancer, which comprises specific premier pairs for testing the single nucleotide polymorphic locus genotypes of a cytochrome P450 1A1 gene (CYP1A1), a cytochrome P450 2E1 gene (CYP2E1), a glutathione-S-transferase M1 gene (GSTM1), a 5,10-methylenetetrahydrofo late reductase gene (MTHFR), a reduction type coenzyme I quinone oxido-reductase gene (NQ01), an oncoprotein 53 gene (P53), an X-ray repair cross-complementing gene 1 (XRCC1) and a xeroderma pigmentosum complementary set A gene (XPA) as well as specific fluorescent probe pairs, fluorescent quantitative PCR regular components, PCR reaction components and the like. The kit of the invention estimates the individual genetic risk of esophageal cancer by synchronously testing the polymorphic locus genotypes of the genes closely related to the genetic risk of esophageal cancer.

The invention discloses a lactic acid bacteria formula for preventing acute and chronic alcoholic liver injury and application thereof. Lactobacillus plantarum KLDS1.0344 and lactobacillus acidophilusKLDS1.0901 have good gastrointestinal fluid tolerance simulating capacity, have certain adhesion capacity to HT-29 cells and have basic probiotic characteristics; the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent acute alcoholic liver injury; and the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 can prevent chronic alcoholic liver injury. Specifically, the lactobacillus plantarum KLDS1.0344 and the lactobacillus acidophilus KLDS1.0901 have the functions of reducing the liver index, improving the intestinal barrier, improving the liver function, reducing the inflammation level in the liver, increasing the content of short-chain fatty acid in the intestinal tract, reducing protein expression of CYP2E1 in the liver and the like.

The invention provides a detection method and a detection kit for quantifying a rat CYP2E1 enzyme based on a characteristic peptide fragment and belongs to the technical field of biodetection and proteins. The method comprises the following steps: screening a characteristic peptide fragment of the rat CYP2E1 enzyme as a quantifying peptide fragment and artificially synthesizing the peptide fragment as an analytical reference substance, and synthesizing a stable isotope labeled peptide fragment as an interior label; carrying out linear regression by taking a specific value of the quantifying peptide fragment and the interior label peptide fragment as a vertical coordinate and the quantifying peptide of a series of standard blood serum samples as a transverse coordinate to obtain a regression equation; releasing the quantifying peptide fragment through enzymolysis of a to-be-detected sample; adding the labeled peptide fragment for feeding analysis; and obtaining the precise content of the rate CYP2E1 enzyme in the samples according to the linear regression equation. Two quantifying peptide fragments are selected to synthesize corresponding labeled peptide fragments as interior labels, thereby achieving a purpose of mutual verification. The detection kit can simply a sample pre-treatment step, so that the rat CYP2E1 enzyme is detected conveniently.

The invention discloses a kit for detecting the gastric cancer susceptibility, which is used for detecting four genes nearly concerned with gastric cancer as follows: MTHFR gene, CYP2E1 metabolic enzyme gene, XRCC1 and ADPRT repairase gene. The kit can simultaneously detect the following SNP (single nucleotide polymorphism) sites: the rs1801133 site of the MTHFR gene, the rs2031920 site of the CYP2E1, the rs25478 site of the XRCC1 gene and the rs1136410 site of the ADPRT gene. By using the kit disclosed by the invention, a group of genes and sites related to the gastric cancer susceptibility are detected, and whether the subject population carry gastric cancer susceptible genes can be judged clearly by using a specific primer and a specific probe by a mononucleotide extension technology combined with a microarray chip technology, thereby screening out the gastric cancer susceptible population from the subject population, changing unhealthy habits and customs and achieving the purpose of prevention.

The invention relates to a detection of four sites of single nucleotide polymorphism (SNP) which are arranged on two human body xenobiotics metabolismenzyme genes including ABCG2 and CYP2E1 and which are associated with the systemic lupus erythematosus (SLE). The invention also can use four sites of single nucleotide polymorphism (SNP) to forecast the liability of systemic lupus erythematosus and to determine the drug to cure the systemic lupus erythematosus. The information provided by the invention is helpful for preventing systemic lupus erythematosus (SLE) and for developing effective new treatments.

Present invention provides a method for screening drug-induced toxicity and screening for drug-induced toxicity by using the NAT2, CYP2E1 and Xanthine Oxidase genes, in particular, provides a method for screening TB drug-induced hepatotoxicity. The method of present invention includes providing test specimen, detection of at least one type of SNPs of the NAT2, CYP2E1 and Xanthine Oxidase genes from the DNA of said test specimen; presence of the SNP genotype indicates the test specimen has a risk for developing anti-TB drug-induced toxicity; said SNP genotype is selected from at least one of the following groups or their combinations thereof: rs1041983, rs1112005, rs1495741, rs1799930, rs1799931, rs1801280, rs1961456, rs2087852, rs11996129, rs2031920, rs2249695, rs3813865, rs3813867, rs1884725, rs2295475 and rs17011368. Moreover, the screening method of the invention includes the test specimen, detection of at least one type of SNPs of the Xanthine Oxidase gene from the DNA of said test specimen; presence of the SNP haplotype indicates the test specimen has a risk for developing high uric acid and its related diseases; said SNP genotype is selected from at least one of the following groups or their combinations thereof: rs1884725, rs2295475 and rs17011368.

The invention relates to a pharmaceutical composite which contains isoniazide, tiopronin or sodium salt thereof that are taken as the active constituents, and a pharmaceutical carrier and/or an excipient, wherein, the mass ratio of the isoniazide and the tiopronin is 1-10:1. The tiopronin has specific action on inhibiting hepatic CYP2E1, and can specifically treat liver damage caused by the isoniazide which is an antituberculotic, and purposefully reduces the toxic and side effect of the isoniazide on the liver. The pharmaceutical composite not only further expands the pharmaceutical value of the tiopronin which is an inhibitor of the hepatic CYP2E1, but also contributes to the safe clinical application of the related pharmaceutical (isoniazide). Therefore, the pharmaceutical composite has important medical value and social and economic benefits.

The invention provides a characteristic peptide fragment for detecting a rat CYP2E1 enzyme and a screening method and an application thereof and belongs to the technical field of biodetection and proteins. The characteristic peptide fragment for detecting the rat CYP2E1 enzyme is high in timeliness, can detect the CYP2E1 enzyme specifically and is relatively high in specificity. The peptide fragment can be better prevented from being interfered, the characteristic peptide fragment is applied to detecting the rat CYP2E1 enzyme, and the effect is obvious; the specific fragment can be obtained bymeans of the screening method for the characteristic peptide fragment for detecting the rat CYP2E1 enzyme.

The invention relates to tiopronin or medical new use of the sodium salt thereof, in particular to the application of the tiopronin or the sodium salt thereof in the preparation of medicine for treating liver functional damage caused by cerebral ischemia, diabetes and obesity. The tiopronin has the function of specifically inhibiting liver cytochrome P450 2E1 (CYP2E1), there protecting the liver function from being damaged caused by cerebral ischemia, diabetes and obesity, so as to be a new clinical use having direction. The new use further expands the medical value of the tiopronin, which is taken as an inhibitor of liver CYP2E1 for protecting the function of liver, thus having important medical value, social and economic benefits.